BACKGROUND: Bright light therapy (BLT) is a well-established treatment for seasonal depression. In the last two decades, the interest in BLT has expanded to involve other nonseasonal types of depression. The role of BLT for nonseasonal depression remains unsettled. In view of the growing number of studies in this area, this review aimed to assess the efficacy of BLT in nonseasonal depression. METHODS: We searched Pubmed; Scopus; PsychINFO; Evidence Based Medicine Guidelines and Cochrane Library until December 2015. The Standardized mean difference was calculated to assess the efficacy of BLT in nonseasonal depression. Data were subgrouped according to different study characteristics. Heterogeneity was assessed by examining the I(2) index. RESULTS: Nine trials met the inclusion criteria. After employing the more conservative random-effects model, the overall model showed a significant reduction of depressive symptoms after BLT administration (SMD=-0.62, P<0.001, I(2)=37%). In particular, BLT appears to be efficacious when administered for 2-5 weeks (SMD=-0.78, P<0.001, I(2)=0%), and as monotherapy (SMD=-0.71, P<0.001, I(2)=18%). Studies of BLT for perinatal depression have found statistically insignificant improvement (SMD=-0.17, P>0.05, I(2)=44%). LIMITATIONS: The overall heterogeneity of the included trials was moderate. The participants were not adequately blinded to the intervention. The sample size was small for certain subgroups. The long-term effect of BLT on depression was not explored. CONCLUSIONS: BLT appears to be efficacious, particularly when administered for 2-5 weeks' duration and as monotherapy. There is an obvious need to optimize the duration and intensity of exposure, the timing and the duration of treatment sessions.
BACKGROUND: Bright light therapy (BLT) is a well-established treatment for seasonal depression. In the last two decades, the interest in BLT has expanded to involve other nonseasonal types of depression. The role of BLT for nonseasonal depression remains unsettled. In view of the growing number of studies in this area, this review aimed to assess the efficacy of BLT in nonseasonal depression. METHODS: We searched Pubmed; Scopus; PsychINFO; Evidence Based Medicine Guidelines and Cochrane Library until December 2015. The Standardized mean difference was calculated to assess the efficacy of BLT in nonseasonal depression. Data were subgrouped according to different study characteristics. Heterogeneity was assessed by examining the I(2) index. RESULTS: Nine trials met the inclusion criteria. After employing the more conservative random-effects model, the overall model showed a significant reduction of depressive symptoms after BLT administration (SMD=-0.62, P<0.001, I(2)=37%). In particular, BLT appears to be efficacious when administered for 2-5 weeks (SMD=-0.78, P<0.001, I(2)=0%), and as monotherapy (SMD=-0.71, P<0.001, I(2)=18%). Studies of BLT for perinatal depression have found statistically insignificant improvement (SMD=-0.17, P>0.05, I(2)=44%). LIMITATIONS: The overall heterogeneity of the included trials was moderate. The participants were not adequately blinded to the intervention. The sample size was small for certain subgroups. The long-term effect of BLT on depression was not explored. CONCLUSIONS: BLT appears to be efficacious, particularly when administered for 2-5 weeks' duration and as monotherapy. There is an obvious need to optimize the duration and intensity of exposure, the timing and the duration of treatment sessions.
Authors: Emma Morton; Erin E Michalak; Anthony Levitt; Robert D Levitan; Amy Cheung; Rachel Morehouse; Rajamannar Ramasubbu; Lakshmi N Yatham; Edwin M Tam; Raymond W Lam Journal: Can J Psychiatry Date: 2020-06-23 Impact factor: 4.356
Authors: David P Cenkner; Helen J Burgess; Brooke Huizenga; Elizabeth R Duval; Hyungjin Myra Kim; K Luan Phan; Israel Liberzon; Heide Klumpp; James Abelson; Adam Horwitz; Ann Mooney; Greta B Raglan; Alyson K Zalta Journal: PLoS One Date: 2022-06-08 Impact factor: 3.752
Authors: Helen J Burgess; Muneer Rizvydeen; Momoko Kimura; Mark H Pollack; Stevan E Hobfoll; Kumar B Rajan; John W Burns Journal: Pain Med Date: 2019-04-01 Impact factor: 3.750